Callan Family Office LLC Buys New Shares in Natera, Inc. $NTRA

Key Points

• Callan Family Office initiated a Natera position by purchasing 3,582 shares valued at approximately $972,000. Institutional investors collectively own 99.90% of the company, with BlackRock also reporting a new multibillion-dollar stake.
• Natera insiders sold shares in the latest quarter, including transactions conducted under Rule 10b5-1 plans to cover tax obligations. Insiders sold 177,955 shares worth approximately $40.7 million, while corporate insiders retain a 5.05% ownership stake.
• Analysts remain broadly bullish, with a consensus rating of “Moderate Buy” and an average price target of $319.38. Natera’s latest quarterly revenue rose 37.7% year over year to $752.75 million, while adjusted EPS of negative $0.47 exceeded expectations.

Callan Family Office LLC bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 3,582 shares of the medical research company's stock, valued at approximately $972,000.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Natera during the 2nd quarter valued at about $2,962,770,000. K.J. Harrison & Partners Inc bought a new stake in Natera in the second quarter valued at approximately $5,117,000. Abbot Financial Management Inc. purchased a new stake in shares of Natera during the second quarter valued at approximately $1,537,000. UBS Group AG increased its stake in shares of Natera by 19.4% in the fourth quarter. UBS Group AG now owns 438,857 shares of the medical research company's stock worth $100,538,000 after buying an additional 71,355 shares during the period. Finally, Fifth Third Bancorp increased its stake in shares of Natera by 3,373.1% in the first quarter. Fifth Third Bancorp now owns 11,253 shares of the medical research company's stock worth $2,251,000 after buying an additional 10,929 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Natera

In related news, CFO Michael Burkes Brophy sold 478 shares of Natera stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total transaction of $131,077.16. Following the completion of the transaction, the chief financial officer directly owned 51,637 shares of the company's stock, valued at $14,159,898.14. This trade represents a 0.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the sale, the insider directly owned 129,019 shares in the company, valued at $34,264,866.02. The trade was a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 177,955 shares of company stock worth $40,704,193. Corporate insiders own 5.05% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Citigroup upped their price objective on shares of Natera from $315.00 to $365.00 and gave the company a "buy" rating in a research note on Thursday, August 13th. Leerink Partners set a $330.00 price target on Natera in a research report on Friday, August 7th. Wells Fargo & Company increased their price objective on Natera from $220.00 to $284.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. Guggenheim lifted their price objective on Natera from $290.00 to $360.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Finally, Evercore restated an "outperform" rating and set a $300.00 target price on shares of Natera in a report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $319.38.

Natera Stock Performance

NTRA stock opened at $327.72 on Tuesday. Natera, Inc. has a fifty-two week low of $157.43 and a fifty-two week high of $333.56. The company has a market capitalization of $47.24 billion, a price-to-earnings ratio of -240.97 and a beta of 1.51. The business's 50 day moving average price is $276.45 and its two-hundred day moving average price is $230.09.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. During the same quarter last year, the business posted ($0.74) EPS. The firm's revenue for the quarter was up 37.7% compared to the same quarter last year. Sell-side analysts forecast that Natera, Inc. will post -1.02 earnings per share for the current year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source